Fees, non-financial help and other from Chiesi, Astrazeneca, GlaxoSmithKline, Boehringer Ingelheim, Merck Sharp Dohme, Pfizer, Takeda, and Mundipharma (outdoors the submitted work); individual fees and non-financial support from Menarini, Novartis, and Zambon. Professor Jones reports personal charges fromsubmit your manuscript | www.dovepress.comInternational Journal of COPD 2015:DovepressDovepressFluticasone propionate/formoterol in COPD 16. Rennard SI, Tashkin DP, McElhattan J, et al. Efficacy and tolerability of budesonide/formoterol in a single hydrofluoroalkane pressurized metereddose inhaler in individuals with chronic obstructive pulmonary illness: final results from a 1-year randomized controlled clinical trial. Drugs. 2009; 69(5):54965. 17. Dransfield MT, Bourbeau J, Jones PW, et al. Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials. Lancet Respir Med. 2013;1(3):21023. 18. Anzueto A, Ferguson GT, Feldman G, et al. Impact of fluticasone propionate/salmeterol (250/50) on COPD exacerbations and impact on patient outcomes. COPD. 2009;six(5):32029. 19. Ferguson GT, Anzueto A, Fei R, Emmett A, Knobil K, Kalberg C. Effect of fluticasone propionate/salmeterol (250/50 microg) or salmeterol (50 microg) on COPD exacerbations.HGF Protein web Respir Med. 2008; 102(8):1099108. 20. Rossi A, Kristufek P, Levine BE, et al; Formoterol in Chronic Obstructive Pulmonary Disease (FICOPD) II Study Group. Comparison of the efficacy, tolerability, and security of formoterol dry powder and oral, slowrelease theophylline in the remedy of COPD. Chest. 2002;121(four): 1058069. 21. Dahl R, Greefhorst LA, Nowak D, et al; Formoterol in Chronic Obstructive Pulmonary Illness I Study Group. Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001;164(5):77884. 22. Bateman ED, Bleecker ER, L vall J, et al. Dose impact of once-daily fluticasone furoate in persistent asthma: a randomized trial. Respir Med. 2012;106(5):64250. 23. Jarad NA, Wedzicha JA, Burge PS, Calverley PM. An observational study of inhaled corticosteroid withdrawal in steady chronic obstructive pulmonary illness. ISOLDE Study Group. Respir Med. 1999;93(3):16166. 24. Lapperre TS, Snoeck-Stroband JB, Gosman MM, et al; Groningen Leiden Universities Corticosteroids in Obstructive Lung Disease Study Group.Agarose ProtocolDocumentation Impact of fluticasone with and without the need of salmeterol on pulmonary outcomes in chronic obstructive pulmonary illness: a randomized trial. Ann Intern Med.PMID:23659187 2009;151(8):51727. 25. Magnussen H, Disse B, Rodriguez-Roisin R, et al; WISDOM Investigators. Withdrawal of inhaled glucocorticoids and exacerbations of COPD. N Engl J Med. 2014;371:1285294. 26. European Medicines Agency. Guideline on Clinical Improvement of Fixed Dose Combination Medicinal Products. EMA/ CHMP/281825/2015. London: European Medicines Agency; 2015. Available from: http://www.ema.europa.eu/docs/en_GB/document_ library/Scientific_guideline/2015/05/WC500186840.pdf. Accessed July 16, 2015. 27. ICH Harmonised Tripartite Guideline: Decision of Manage Group and Connected Issues in Clinical Trials. E10. ICH; 2000. Readily available from: http:// www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/ Efficacy/E10/Step4/E10_Guideline.pdf. Accessed July 16, 2015. 28. Wedzicha JA, Calverley PM, Seemungal TA, Hagan G, Ansari Z, Stockley RA; INSPIRE Investigators. The preventi.